tradingkey.logo

U.S. FDA awards Year Two funds to Palvella's Phase 3 Selva trial

ReutersOct 13, 2025 11:40 AM

- Palvella Therapeutics Inc PVLA.O:

  • U.S. FOOD AND DRUG ADMINISTRATION AWARDS YEAR TWO PROCEEDS FROM ORPHAN PRODUCTS GRANT SUPPORTING PALVELLA THERAPEUTICS’ PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS

  • PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED Q1 2026; NDA SUBMISSION H2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI